Delving into the Latest Updates on Inactivated Influenza Vaccine(Emory University/Georgia Institute of Technology) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine

Synonyms

Inactivated Influenza Vaccine (microneedle patch)(Emory University/Georgia Institute of Technology)

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Influenza, Human

Originator Organization

Emory University

Active Organization-

Inactive Organization

Emory University

Georgia Institute of Technology

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of the study is to better understand how the use of antibiotics changes micro-organisms in the intestines. The change to micro-organisms in the intestines may change the body's vaccine immune response and alter the effectiveness of the IIV (seasonal flu) vaccine.
In particular, the investigators will be looking at certain markers in blood after vaccination with IIV (seasonal flu vaccine) with or without the use of antibiotics before vaccination.
There will be two randomized groups. Group A will start taking antibiotic by mouth 3 days prior to vaccination and continue taking antibiotics the day of vaccination and one day after vaccination for a total of 5 days. Group B will only receive the IIV (seasonal flu vaccine) and will not take any antibiotics.
The investigators hope to enroll 50 subjects at Emory.

Start Date01 Apr 2015

Sponsor / Collaborator

Emory University

NCT00841646

/ CompletedPhase 2

A Phase II, Open-label, Multi-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects

The present study will evaluate the immunogenicity, safety and tolerability of two doses of monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult and Elderly Subjects.

Start Date01 Dec 2008

Sponsor / Collaborator-

100 Clinical Results associated with Inactivated Influenza Vaccine(Emory University/Georgia Institute of Technology)

Login to view more data

100 Translational Medicine associated with Inactivated Influenza Vaccine(Emory University/Georgia Institute of Technology)

Login to view more data

100 Patents (Medical) associated with Inactivated Influenza Vaccine(Emory University/Georgia Institute of Technology)

Login to view more data

3

Literatures (Medical) associated with Inactivated Influenza Vaccine(Emory University/Georgia Institute of Technology)

01 Jan 2023·Theranostics

Developing an efficient MGCR microneedle nanovaccine patch for eliciting Th 1 cellular response against the SARS-CoV-2 infection.

Article

Author: Zhang, Amin ; Gao, Ang ; Liang, Hui ; Cui, Xinyuan ; Cui, Daxiang ; Chen, Yunsheng

Rationale: Novel vaccine R&D is essential to interrupt the COVID-19 pandemic and other epidemics in the future. Subunit vaccines have received tremendous attention for their low cost and safety. To improve the immunogenicity of subunit vaccines, we developed a novel vaccine adjuvant system. Methods: Here we rationally designed a CpG 1018 and graphene oxide-based bi-adjuvant system to deliver the Receptor-Binding Domain (RBD) of the SARS-CoV-2 spike protein and obtained the graphene oxide-based complex adjuvant nanovaccine (GCR). Furthermore, we developed a microneedle patch vaccine (MGCR) based on the GCR vaccine. Results: GCR nanovaccine displayed superb antigen loading and encapsulation efficiency. Two dosages of vaccination of GCR nanovaccine could elicit adequate RBD-specific binding antibody response with 2.14-fold higher IgG titer than Alum adjuvant vaccine. The peptide pools assay demonstrated the robust RBD-specific Type 1 Cellular response induced by the GCR nanovaccine in CD8⁺ T cells. Furthermore, we prepared an MGCR microneedle patch, which generated a similar RBD-specific binding antibody response to the GCR vaccine, sustained a high antibody level above 16 weeks, and significantly elevated the T_cm proportion in mouse spleen. The MGCR microneedle patch vaccine also could be stably stored at room temperature for several months and administrated without medical staff, which maximizes the vaccine distribution efficiency. Conclusion: The vaccine system could significantly improve the vaccine distribution rate in low-income areas and offer a potential vaccination approach to fight against the SARS-Cov-2 infection and other pandemics occurred in the future.

14 Feb 2018·Science Translational MedicineQ1 · MEDICINE

Circulating T _FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity

Q1 · MEDICINE

Article

Author: Laurie, Karen L. ; Mannering, Stuart I. ; Loudovaris, Thomas ; Wheatley, Adam K. ; Fox, Annette ; Rockman, Steve ; Elliot, Michael ; Hurt, Aeron C. ; Westall, Glen P. ; Nguyen, Thi H. O. ; Nüssing, Simone ; Loh, Liyen ; Sant, Sneha ; Kent, Stephen J. ; Lappas, Martha ; Kedzierska, Katherine ; Tangye, Stuart G. ; Wakim, Linda M. ; Chung, Amy W. ; Clemens, E. Bridie ; Koutsakos, Marios

Analysis of influenza-specific B cells during antigen exposure and tissue compartmentalization provides insights into human B cell memory.

01 Feb 1998·International Journal of EpidemiologyQ1 · MEDICINE

The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination

Q1 · MEDICINE

Article

Author: Eli Schwartz ; David Raveh

BACKGROUNDHepatitis A (HA) is the most common vaccine-preventable disease among travellers. The probability of contracting the disease depends on the endemicity in both the destination and country of origin of the traveller. The introduction of the new highly effective but expensive inactivated HA vaccine necessitates a re-evaluation of HA prevention policy. In highly developed countries all travellers require vaccination. In highly endemic areas the entire population is immune. In Israel, HA seroprevalence declined from 94% in the early 1970s to < 60% in the mid 1980s. Living in a country in which the HA endemicity is changing, we studied the current situation of HA seroprevalence among travellers and the cost-benefit of screening for HA IgG before vaccination.METHODSIsraeli travellers of all ages, (range 22-74 years) expecting to spend a considerable time abroad presented to the travel clinic for pre travel advice and vaccination. A brief medical history was taken, including history of jaundice. Blood for HA IgG testing was drawn.RESULTSIn the present study, 389 Israeli travellers were screened for HA IgG. Overall, 46% were seropositive: 26% in the 21-30 group (n = 102); 37% in the 31-40 group (n = 145); 62% in the 41-50 group (n = 62); and 79% in the > 50 group (n = 80).CONCLUSIONSIn countries where hepatitis A endemicity is changing, an evaluation of seroprevalence and then a cost benefit calculation should be made. In Israel, assuming a current cost of $130 for vaccination and $30 for the IgG test, it is economically valid to screen Israeli travellers > 30 years old for HAV IgG before vaccination. A formula is presented for calculating the cost benefit ratio in any country, based on local endemicity according to age group.

100 Deals associated with Inactivated Influenza Vaccine(Emory University/Georgia Institute of Technology)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 1	US	Emory University	24 Jun 2015
Influenza, Human	Phase 1	US	Georgia Institute of Technology	24 Jun 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02154061 (VAX-002, CTgov)	Not Applicable	Influenza, Human	33	IIV Flu Vaccine+metronidazole+Neomycin+Vancomycin (IIV Flu Vaccine With Antibiotics)	nyzoesqoey(hgyhhkcnzy) = bwsommhgjy pnmfiffyrw (uwrjalkjbl, rwhaexlvxl - wcqhlcirjx) View more	-	27 Jun 2018
				IIV Flu Vaccine (IIV Flu Vaccine)	nyzoesqoey(hgyhhkcnzy) = jjdwdsbali pnmfiffyrw (uwrjalkjbl, harfkxrrys - wjzbuaykjj) View more